Pre-market hot trades in US stocks: QVC up 7.79% pre-market; Amer Sports up 7.01% pre-market

Tracking Unusual Activity
2025.09.18 12:12
portai
I'm PortAI, I can summarize articles.

QVC pre-market up 7.79%; Amer Sports pre-market up 7.01%; 89bio pre-market up 87.38%; Aptevo Therap pre-market up 60.94%; Datavault AI pre-market up 53.55%

Pre-market Hot Trades in US Stocks

Amer Sports is up 7.01% in pre-market trading. According to recent key news:

  1. On September 18, Amer Sports raised its financial guidance for the third quarter of 2025, expecting revenue growth to exceed 20%, with adjusted operating profit margins reaching or exceeding the high end of 12% to 13%. This news drove the stock price up. Source: MT Newswires.

  2. On September 18, Amer Sports reaffirmed its long-term financial algorithm during its Investor Day event and raised its financial guidance for the third quarter, with CEO James Zheng expecting strong quarterly performance across all departments. Source: Reuters.

  3. On September 17, the trend of recovering consumer investment enhanced market confidence in consumer stocks like Amer Sports, driving the stock price up. Source: Investor Commentary. The consumer sector is recovering, and market confidence is strengthening.

Top Gainers in Pre-market US Stocks

89bio is up 87.38% in pre-market trading. Based on recent important news:

  1. On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news led to a significant increase in 89bio's stock price.

  2. On September 18, 89bio's key drug pegozafermin is considered to have great potential in treating moderate to severe metabolic dysfunction-associated steatotic liver disease (MASH), further boosting market confidence in its future development.

  3. On September 18, analysts expressed optimism about 89bio's acquisition deal, believing in the huge market potential of MASH, supporting a buy rating for the stock. The biopharmaceutical industry is active in mergers and acquisitions, increasing market volatility.

Aptevo Therapeutics is up 60.94% in pre-market trading. Based on recent key news:

  1. On September 16, Aptevo Therapeutics announced that its acute myeloid leukemia (AML) RAINIER trial's Cohort 3 achieved a 100% remission rate. This news drove the company's stock price up by 57%.

  2. On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months.

  3. On September 17, despite facing financial challenges, Aptevo's positive progress in its oncology pipeline provides potential upside for the future. The biotechnology sector has been active recently.

Datavault AI is up 53.55%. No recent news

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.